Chemical Structure (Image 1)
Bupropion Hydrochloride Tablet, Film Coated, Extended Release
Product Images NDC 0591-3540
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Bupropion Hydrochloride (NDC 0591-3540). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Actavis Pharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Ndc 0591-3540-60 Twice-a-day (after Initial Titration) Bupropion HCl Extended-release Tablets, Usp (sr) 100 mg* (Image 2)
This is a medication guide for BuPROPion HCI Extended-Release Tablets, USP (SR) with NDC 0591-3540-60. The tablets contain 100mg of Bupropion hydrochioride and are meant for twice-a-day use after initial titration. The medication guide contains a warning not to use in combination with ZYBAN or any other medications containing bupropion hydrochloride. Each tablet is meant to be taken orally and pharmacist is advised to dispense the accompanying medication guide to each patient. The usual dosage should be taken as per the instructions on the package insert. The tablets should be stored at 20° o 25°C (68" to 77°F). The medication is manufactured by Teva Pharmaceuticals.*
Ndc 0591-3541-60 Twice-a-day (after Initial Titration) Bupropion HCl Extended-release Tablets, Usp (sr) 150 mg* (Image 3)
This is a description of a medication called Bupropion HCI, which is an extended-release tablet usually taken twice per day. The tablets contain 150mg of Bupropion hydrochloride, a potent medication that should not be combined with ZYBAN or any other drug containing Bupropion hydrochloride. The packaging recommends storing the medication at 68°F to 77°F, and the accompanying medication guide must be given to each patient along with the tablets. Additionally, the tablets are manufactured by Teva Pharmaceuticals, and caution is given to keep them away from children. Finally, there's a serialization coding area on the packaging.*
Ndc 0591-3542-60 Twice-a-day (after Initial Titration) Bupropion HCl Extended-release Tablets, Usp (sr) 200 mg* (Image 4)
This is a warning label for a medication with the NDC code 0591-3542-60. The medication is an extended-release version of Bupropion HCI, which comes in tablet form with each tablet containing 200mg of the active ingredient. It is intended to be taken twice a day, with dosage instructions provided in the package insert. Patients should not use this medication in combination with another medication that contains Bupropion HCI, such as ZYBAN. The medication guide should be dispensed to every patient, and the medication should be stored at controlled room temperature. The manufacturer of the medication is Teva Pharmaceuticals.*
* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.
